Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free BCT Stock Alerts

BriaCell Therapeutics (BCT) Competitors

BriaCell Therapeutics logo
C$4.95 -0.10 (-1.98%)
As of 03:59 PM Eastern
Compare

BCT vs. HBP, SCYB, COM, NVH, and PDP

Should you buy BriaCell Therapeutics stock or one of its competitors? BriaCell Therapeutics's main competitors and comparable companies include Helix BioPharma (HBP), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), and Pediapharm (PDP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BriaCell Therapeutics compare to Helix BioPharma?

BriaCell Therapeutics (TSE:BCT) and Helix BioPharma (TSE:HBP) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

Helix BioPharma is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A

In the previous week, Helix BioPharma had 1 more articles in the media than BriaCell Therapeutics. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for BriaCell Therapeutics. Helix BioPharma's average media sentiment score of 0.75 beat BriaCell Therapeutics' score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the news media.

Company Overall Sentiment
BriaCell Therapeutics Neutral
Helix BioPharma Positive

Helix BioPharma's return on equity of -21.54% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BriaCell TherapeuticsN/A -147.92% -122.71%
Helix BioPharma N/A -21.54%-279.98%

0.0% of BriaCell Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Helix BioPharma shares are held by institutional investors. 9.3% of BriaCell Therapeutics shares are held by company insiders. Comparatively, 2.2% of Helix BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

BriaCell Therapeutics has a beta of 1.96435, suggesting that its stock price is 96% more volatile than the broader market. Comparatively, Helix BioPharma has a beta of 0.433836, suggesting that its stock price is 57% less volatile than the broader market.

Summary

BriaCell Therapeutics beats Helix BioPharma on 6 of the 10 factors compared between the two stocks.

How does BriaCell Therapeutics compare to Scythian Biosciences?

BriaCell Therapeutics (TSE:BCT) and Scythian Biosciences (CVE:SCYB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Scythian Biosciences' return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BriaCell TherapeuticsN/A -147.92% -122.71%
Scythian Biosciences N/A N/A N/A

0.0% of BriaCell Therapeutics shares are owned by institutional investors. 9.3% of BriaCell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, BriaCell Therapeutics' average media sentiment score of 0.00 equaled Scythian Biosciences'average media sentiment score.

Company Overall Sentiment
BriaCell Therapeutics Neutral
Scythian Biosciences Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A
Scythian BiosciencesN/AN/AN/AN/AN/A

Summary

BriaCell Therapeutics and Scythian Biosciences tied by winning 2 of the 4 factors compared between the two stocks.

How does BriaCell Therapeutics compare to 138267 (COM.TO)?

BriaCell Therapeutics (TSE:BCT) and 138267 (COM.TO) (TSE:COM) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

138267 (COM.TO)'s return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BriaCell TherapeuticsN/A -147.92% -122.71%
138267 (COM.TO) N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A
138267 (COM.TO)N/AN/AN/AN/AN/A

In the previous week, BriaCell Therapeutics' average media sentiment score of 0.00 equaled 138267 (COM.TO)'saverage media sentiment score.

Company Overall Sentiment
BriaCell Therapeutics Neutral
138267 (COM.TO) Neutral

0.0% of BriaCell Therapeutics shares are held by institutional investors. 9.3% of BriaCell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

BriaCell Therapeutics and 138267 (COM.TO) tied by winning 2 of the 4 factors compared between the two stocks.

How does BriaCell Therapeutics compare to Novoheart?

Novoheart (CVE:NVH) and BriaCell Therapeutics (TSE:BCT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

BriaCell Therapeutics has lower revenue, but higher earnings than Novoheart. Novoheart is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NovoheartC$423.50K236.08-C$7.17M-C$0.04N/A
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A

In the previous week, Novoheart's average media sentiment score of 0.00 equaled BriaCell Therapeutics'average media sentiment score.

Company Overall Sentiment
Novoheart Neutral
BriaCell Therapeutics Neutral

0.0% of BriaCell Therapeutics shares are owned by institutional investors. 9.3% of BriaCell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Novoheart's return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
NovoheartN/A N/A N/A
BriaCell Therapeutics N/A -147.92%-122.71%

Summary

Novoheart and BriaCell Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does BriaCell Therapeutics compare to Pediapharm?

Pediapharm (CVE:PDP) and BriaCell Therapeutics (TSE:BCT) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

BriaCell Therapeutics has lower revenue, but higher earnings than Pediapharm. BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Pediapharm, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PediapharmC$11.16M5.95-C$16.15M-C$0.07N/A
BriaCell TherapeuticsN/AN/A-C$2.37M-C$0.84N/A

In the previous week, Pediapharm's average media sentiment score of 0.00 equaled BriaCell Therapeutics'average media sentiment score.

Company Overall Sentiment
Pediapharm Neutral
BriaCell Therapeutics Neutral

0.0% of BriaCell Therapeutics shares are held by institutional investors. 9.3% of BriaCell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Pediapharm's return on equity of 0.00% beat BriaCell Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
PediapharmN/A N/A N/A
BriaCell Therapeutics N/A -147.92%-122.71%

Summary

Pediapharm beats BriaCell Therapeutics on 5 of the 8 factors compared between the two stocks.

Get BriaCell Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCT vs. The Competition

Export
MetricBriaCell TherapeuticsBiotechnology IndustryHealthcare SectorTSE Exchange
Market CapC$43.07MC$4.02BC$7.21BC$12.38B
Dividend Yield13.70%3.61%2.54%6.24%
P/E Ratio-5.8912.31273.2139.34
Price / SalesN/A1,403.34639.269.80
Price / CashN/A106.6377.2082.29
Price / Book1.5316.2112.864.68
Net Income-C$2.37M-C$22.72MC$3.47BC$299.09M
7 Day Performance-11.92%-1.18%-0.22%-1.51%
1 Month Performance2.70%12.75%8.04%4.09%
1 Year Performance-57.80%53.86%25.08%27.89%

BriaCell Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BCT
BriaCell Therapeutics
N/AC$4.95
-2.0%		N/A-52.8%C$43.07MN/AN/A16
HBP
Helix BioPharma
N/AC$1.94
-2.5%		N/A+31.6%C$148.17MN/AN/A9
SCYB
Scythian Biosciences
N/AC$3.49
-5.9%		N/A+0.0%C$102.38MN/AN/AN/A
COM
138267 (COM.TO)
N/AN/AN/AN/AC$102.19MN/AN/AN/A
NVH
Novoheart
N/AC$0.53
+1.9%		N/A+0.0%C$99.98MC$423.50KN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:BCT) was last updated on 9/2/2026 by MarketBeat.com Staff.
From Our Partners
#1 Stock to Own as Trump Launches Historic Mission Backing "Medical AI"
The federal government is throwing its full support behind a new class of AI technology, in what's being calle...
Stansberry Research | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Jon Najarian's #1 Energy Trade for 2026
Elon Musk just built the largest private power network in American history. Hall of Fame Trader Jon Najarian s...
Banyan Hill Publishing | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Musk says UBI is coming. I say it's already here.
Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...
Freedom Financial | Sponsoredtc pixel
Billionaire Mutual Fund Manager Makes Shocking Prediction
Thirty-two minutes into SpaceX's first earnings call, Elon Musk quietly revealed a new initiative that's turni...
InvestorPlace | Sponsoredtc pixel
What the Mainstream Media Gets Wrong About IPO Investing
Jason Bodner spent nearly two decades helping IPOs go to market. Now he says an overlooked group of companies ...
Brownstone Research | Sponsoredtc pixel